logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Panel Rejects Hemispherx's Ampligen For Chronic Fatigue Syndrome; Stock Down

Hemispherx Biopharma Inc. (HEB) announced the outcome of the meeting of the Arthritis Advisory Committee of the U.S. Food and Drug Administration on the New Drug Application or "NDA" for Ampligen for Chronic Fatigue Syndrome or "CFS".

The vote was 8 to 5 against recommending the approval of Ampligen. However, the Advisory Committee backed safety profile of Ampligen.

Hemispherx said it is committed to the Ampligen clinical development program and to bringing Ampligen to market to ease the suffering of those seriously afflicted with CFS. The company said it will also continue to work closely with the FDA to support the review of this investigational compound. Hemispherx will seek to do everything necessary to confirm in a scientifically rigorous manner that Ampligen is a safe and effective treatment for CFS.

The Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review of the NDA is February 2, 2013.

HEB is currently trading at $0.28, down $0.08 or 21.39 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Palo Alto Networks, Inc. (PANW) shares are down about 7%, but we think the stock is overreacting. We believe the tidings are not all that bad. Quarterly results and guidance are a mixed bag, in fact. Watch the slide show for more details. Mortgage application volume rose last week, ending two straight weeks of declines, as interest rates held steady. The Market Composite Index, a measure of mortgage loan application volume, increased 2.8 percent on a seasonally adjusted basis for the week ending August 26, from one week earlier, according to the Mortgage Bankers Association or MBA. As part of the launch of "Rogue One: A Star Wars Story," a new toyline was unveiled on Wednesday in a stop motion video created by fans. A series of original animated shorts from Star-war fans starring key toys were used to create the video.
comments powered by Disqus
Follow RTT